New IPF drug ENV-101 tested with standard meds in healthy volunteers
NCT ID NCT07454291
First seen Mar 10, 2026 · Last updated May 16, 2026 · Updated 12 times
Summary
This early-stage study looks at how the experimental drug ENV-101 interacts with two standard IPF medicines, nintedanib and pirfenidone, in healthy adults. Researchers will measure drug levels in the blood to understand safety and dosing. The study involves 57 participants across four groups, with treatment lasting up to 30 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGBrisbane, Queensland, 4006, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Research Site
RECRUITINGMelbourne, Victoria, 3004, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.